$OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery$

PremiumPress Releases

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

22d ago

OKYO

PremiumPress Releases

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

1M ago

OKYO

PremiumPress Releases

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

1M ago

OKYO

PremiumPress Releases

OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event

1M ago

OKYO

PremiumPress Releases

OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

2M ago

OKYO

PremiumPress Releases

OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024

4M ago

OKYO

More OKYO News >

OKYO News on the Web

2024-04-09

OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event

Proactive Investors

Neutral

2024-04-09

OKYO Pharma to include additional analyses in upcoming dry eye disease Key Opinion Leader event

Proactive Investors

Neutral

2024-04-08

OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024

Yahoo Finance

Neutral

2024-04-02

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Yahoo Finance

Neutral

2024-03-22

OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms

Proactive Investors

Neutral

2024-03-22

Yahoo Finance

Neutral

2024-03-21

OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease

Proactive Investors

Neutral

2024-03-21

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial

Yahoo Finance

Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score

Media Buzz

This Week0 articles

Weekly Average0 articles

News Sentiment

Currently, no data available

See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OKYO’s Media Buzz Sentiment?

Currently, no data Available

What is OKYO’s weekly average amount of articles?

Currently, no data Available

What is OKYO’s News Sentiment?

Currently, no data Available

Healthcare Stocks that are Trending in the News

ELVElevance Health

EWEdwards Lifesciences

INSPInspire Medical Systems

CGEMCullinan Management

MRNSMarinus

Showing the stocks with the most bullish news sentiment over the past week

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing